Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMJ1YQ2)

Drug Name	Epeleuton DMJ1YQ2
Synonyms	Epeleuton; Epeleuton [INN]; 1667760-39-5; FA9BPX1T6V; (S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; UNII-FA9BPX1T6V; 15(S)-HEPE-EE; CHEMBL5095178; AKOS040748327; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER
Drug Type	Small molecule
Structure
Structure	3D MOL			2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

4 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Sickle-cell disorder	DISW25G5	3A51	Phase 2	[1]
Type 2 diabetes	DISJ9M77	5A11	Phase 2	[2]
Hypertriglyceridemia	DIS7SN6U	5C80.1	Phase 2	[2]
Non-alcoholic fatty liver disease	DISDG1NL	DB92	Phase 2	[3]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05861453) An Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients With Sickle Cell Disease. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT04365400) A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes. U.S.National Institutes of Health.
3	ClinicalTrials.gov (NCT02941549) A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered Epeleuton In NAFLD Patients. U.S.National Institutes of Health.